Register now to R3i !
Your login
Your password
Confirm your password
Your email
I agree to receive the R3i newsletter

Residual Risk through Landmark Studies

During the last 15 years, large prospective clinical trials have proven that :
  • - statin therapy may reduce the risk of major cardiovascular events by 25 to 35%. However, despite effective low-density lipoprotein cholesterol (LDL-C) lowering treatment, significant cardiovascular (CV) risk persists.
  • - even aggressive multifactorial therapy (statins, blood pressure lowering agents, anti-diabetic agents) did not prevent the development or progression of microvascular complications in patients with type 2 diabetes.

This section propose to put the results of these large clinical trials into perspective both on macro- and microvascular residual risk.
Macrovascular Residual Risk Studies
Microvascular Residual Risk Studies
Macro- and Microvascular Residual Risk Studies